KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $20.0 million.

  • Nektar Therapeutics' Non-Current Assets fell 695.83% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.8 million, marking a year-over-year decrease of 4846.37%. This contributed to the annual value of $42.6 million for FY2024, which is 3679.38% down from last year.
  • As of Q3 2025, Nektar Therapeutics' Non-Current Assets stood at $20.0 million, which was down 695.83% from $21.0 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Non-Current Assets high stood at $357.5 million for Q1 2021, and its period low was $20.0 million during Q3 2025.
  • Its 5-year average for Non-Current Assets is $137.3 million, with a median of $70.7 million in 2023.
  • As far as peak fluctuations go, Nektar Therapeutics' Non-Current Assets tumbled by 7619.09% in 2023, and later soared by 778.05% in 2024.
  • Over the past 5 years, Nektar Therapeutics' Non-Current Assets (Quarter) stood at $321.6 million in 2021, then plummeted by 48.81% to $164.6 million in 2022, then plummeted by 59.1% to $67.3 million in 2023, then crashed by 36.79% to $42.6 million in 2024, then plummeted by 53.03% to $20.0 million in 2025.
  • Its last three reported values are $20.0 million in Q3 2025, $21.0 million for Q2 2025, and $26.3 million during Q1 2025.